Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas

Key Points

• Smith Chas P & Associates PA Cpas reduced its Johnson & Johnson stake by 2.6% in the second quarter, selling 6,543 shares and retaining 245,396 shares valued at approximately $62.3 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly EPS of $2.90, exceeding estimates, while revenue rose 6.6% year over year to $25.31 billion. The company maintains a $1.34 quarterly dividend, equivalent to a 2.0% yield.
• Analysts remain moderately bullish, with a consensus price target of $274.13 and recent targets ranging as high as $320. Positive lung-cancer trial results and solid underlying growth support the outlook, though Stelara sales declines and insider selling remain concerns.

Smith Chas P & Associates PA Cpas decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 245,396 shares of the company's stock after selling 6,543 shares during the quarter. Johnson & Johnson comprises 3.0% of Smith Chas P & Associates PA Cpas' holdings, making the stock its 10th largest position. Smith Chas P & Associates PA Cpas' holdings in Johnson & Johnson were worth $62,323,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $28,000. Blueline Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $25,000. Matrix Trust Co increased its position in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson during the second quarter worth about $43,000. Finally, MidAtlantic Capital Management Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at about $37,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive lung-cancer trial results: New data showed that RYBREVANT-based regimens improved survival outcomes in patients with EGFR-mutated non-small-cell lung cancer. The PAPILLON study reported the longest median overall survival yet reported for first-line treatment of EGFR exon 20 insertion disease, while the COPERNICUS study indicated improved tolerability and fewer treatment-related adverse events. These results strengthen the commercial outlook for JNJ’s oncology portfolio. Johnson & Johnson Reports Stronger Survival Data in EGFR-Mutated Lung Cancer
• Positive Sentiment: Defensive-investment appeal: Market commentary highlighted Johnson & Johnson as a defensive dividend stock with a strong balance sheet, rising payouts and share-repurchase potential. That positioning may attract investors amid ongoing Federal Reserve and inflation concerns. The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
• Positive Sentiment: Underlying growth remains solid: Despite declining Stelara sales, management has emphasized that underlying revenue growth remains healthy. Recent analysis noted that reported sales still increased 5.6% despite an approximately 460-basis-point Stelara drag, supporting the case that JNJ’s broader portfolio is gaining momentum. Should You Judge JNJ Stock Without Stelara?
• Neutral Sentiment: At the Deutsche Bank Healthcare Summit, JNJ presented its business outlook and strategy, but the available transcript listing did not identify a specific new announcement likely to materially change near-term valuation. Johnson & Johnson Presents at Deutsche Bank 2026 Healthcare Summit
• Negative Sentiment: JNJ’s gain trailed the broader market, suggesting that the session’s move was more defensive and company-specific than a sign of broad risk-taking. Its elevated valuation also leaves less room for disappointment if Stelara-related pressure persists.

Insider Buying and Selling

In other news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock worth $23,064,544 over the last 90 days. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $270.65 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $173.33 and a 52-week high of $281.07. The firm has a market cap of $652.24 billion, a PE ratio of 31.36, a price-to-earnings-growth ratio of 2.55 and a beta of 0.24. The company's 50 day moving average is $263.49 and its two-hundred day moving average is $246.55.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts expect that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JNJ. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a report on Monday, July 13th. The Goldman Sachs Group reissued a "buy" rating and set a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. Finally, HSBC increased their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $274.13.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.